Related Experiment Video
Updated: Apr 27, 2026
10:04
Quantification of Cerebral Vascular Architecture using Two-photon Microscopy in a Mouse Model of HIV-induced Neuroinflammation
Published on: January 12, 2016
8.1K
Cannabinoid receptor-2 and HIV-associated neurocognitive disorders
Summary
Cannabinoid receptor-2 (CB2) activation may help treat HIV-associated neurocognitive disorders (HAND) by reducing brain inflammation and HIV replication. This approach offers a promising adjunctive therapy for patients on highly active antiretroviral therapy (HAART).
Area of Science:
- Neuroscience
- Immunology
- Virology
Background:
- Highly active antiretroviral therapy (HAART) has reduced but not eliminated HIV-associated neurocognitive disorders (HAND).
- Subtle brain macrophage and microglial activation persist in HAART-treated patients, indicating ongoing neuroinflammation.
- Adjunctive therapies are needed to suppress HIV replication and neuroinflammation in the brain.
Purpose of the Study:
- To explore the potential of cannabinoid receptor-2 (CB2) activation as an adjunctive therapy for HAND.
- To investigate how CB2 activation can inhibit HIV replication and reduce neuroinflammation.
Main Methods:
- The study discusses the mechanisms by which CB2 activation impacts HIV replication and neuroinflammation.
- It reviews the effects of CB2 activation on immune cells like macrophages and microglia.
- The potential benefits of CB2 agonists in attenuating neuronal injury and blood-brain barrier permeability are examined.
Main Results:
- CB2 activation inhibits HIV replication, reducing the production of neurotoxins.
- It down-regulates inflammation by blunting macrophage and microglial activation and decreasing pro-inflammatory cytokines.
- CB2 activation reduces blood-brain barrier permeability and leukocyte infiltration, mitigating neuronal injury.
Conclusions:
- CB2 agonists represent a promising therapeutic strategy to attenuate HAND in patients on HAART.
- By inhibiting viral replication and neuroinflammation, CB2 activation can prevent neuronal and synaptic loss.
- CB2 activation may also offer neuroprotection against drug addiction-related brain injury.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
1.1K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.4K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.4K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.8K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.8K
01:23Alzheimer Disease ll: Pathophysiology
27
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
27
01:29Drugs Affecting Neurotransmitter Synthesis
2.5K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K